Related Experiment Video

Updated: Jul 2, 2026

High Content Screening in Neurodegenerative Diseases
13:32

High Content Screening in Neurodegenerative Diseases

Published on: January 6, 2012

Drug discovery and development for Huntington's disease - an orphan indication with high medical need

Freddy Heitz1, Salvatore La Rosa, Eduardo Gonzalez-Couto

  • 1Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy. gterstappen@sienabiotech.com

Idrugs : the Investigational Drugs Journal
|September 3, 2008
PubMed

Insights

Huntington's disease (HD) is a rare neurodegenerative disorder affecting motor control and mental capacity. While no cure exists, increased research and drug development offer hope for new treatments for this orphan disease.

Area of Science:

  • Neurodegenerative diseases
  • Genetics and rare diseases

Background:

  • Huntington's disease (HD) is a rare, inherited neurodegenerative disorder.
  • It causes progressive deterioration of mental capacity and motor control, characterized by chorea (involuntary movements).
  • Current treatments are largely symptomatic and not highly effective, leaving a significant unmet medical need.

Purpose of the Study:

  • To review the current landscape of therapeutic development for Huntington's disease.
  • To highlight the growing interest and investment in finding treatments for this orphan condition.

Main Methods:

  • Literature review of recent advancements in Huntington's disease research.
  • Analysis of trends in drug discovery and development for orphan neurological disorders.

Main Results:

  • A significant increase in the number of compounds under investigation for HD treatment.
  • Growing support from legislative incentives and non-profit foundations driving research.

Conclusions:

  • Despite the lack of disease-modifying therapies, the pipeline for Huntington's disease treatments is expanding.
  • Increased research efforts and funding provide optimism for future therapeutic options for HD patients.

More Related Videos

Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy11:22

Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy

Published on: June 27, 2018

Ole Isacson: Development of New Therapies for Parkinson's Disease23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Related Concept Videos

Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...